Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 812 of 6351
-
Glow-in-the-Dark dye helps surgeons spot hidden lung cancer
Diagnosis CompletedThis is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ens…
Phase 2 • Sponsor: Vergent Bioscience, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of …
Phase 1/2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
A new pill takes aim at diabetic nerve pain — will it work?
Symptom relief CompletedThe main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Breath test could revolutionize lung cancer detection
Diagnosis CompletedThe Phase 2a Evolution study aims to assess the diagnostic accuracy of the OWL-EV1 Probe Breath Biopsy Test to differentiate between individuals with lung cancer and relevant contrast groups. The contrast groups will be representative of the clinical populations in which the tes…
Phase 2 • Sponsor: Owlstone Ltd • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined …
Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a higher dose of reblozyl free MDS patients from frequent transfusions?
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
A mailed kit and a chat: a new push to screen more latina women for cervical cancer
Prevention CompletedThe goal of this study is to learn if women of Hispanic/Latina ethnicity are willing to self-collect a cervico-vaginal sample for HPV testing. The main question the study will answer is: • Does a brief educational intervention increase the feasibility and acceptability of HPV se…
Sponsor: Fox Chase Cancer Center • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail shows promise for rare leukemia
Disease control OngoingOpen-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough prostate cancer: drug cocktail trial launches
Disease control Recruiting nowAsymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testo…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could CBD help curb opioid cravings? new study investigates
Disease control CompletedThe long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of our project was an open cross-over design study in healthy individuals to confirm the safety and pharmacoki…
Phase 2 • Sponsor: Yasmin Hurd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic TRK-950 joins forces with standard chemo to fight stomach cancer
Disease control Recruiting nowThis study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junc…
Phase 2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Targeted drug aims to prevent second heart attacks
Disease control Recruiting nowThis is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separ…
Phase 3 • Sponsor: DalCor Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Blood test could help doctors switch cancer drugs faster
Disease control Recruiting nowThis phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the b…
Phase 2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThe Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could changing when chemo is given boost immunotherapy for head and neck cancer?
Disease control Recruiting nowThe rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 mono…
Phase 2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Spinal stimulation offers new hope for autonomic recovery after injury
Symptom relief Recruiting nowThis study is a pilot clinical trial to explore the efficacy of transcutaneous spinal cord stimulation (TCSCS) (proof-of-concept) in mitigating crucial autonomic dysfunctions that impact the health-related quality of life of individuals with spinal cord injury (SCI).
Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowJuvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and s…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for rare kidney disease: iptacopan trial aims to protect kidneys
Disease control Recruiting nowThis study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New bed nets take on mosquito resistance in malaria battle
Disease control OngoingThe investigator plan to conduct a three-arm cluster-randomized control trial which compares two next generation of long-lasting Insecticidal Nets (LLINs); Veeralin®LLIN (PBO-py LLIN), Interceptor G2 (chlorfenapyr-py LLIN) to a standard py-LLIN in the department of Tiebissou Sout…
Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can an online course cut sexual assault on campus? large trial aims to find out
Prevention Recruiting nowThe goal of this randomized trial is to test whether the Internet-Delivered Enhanced Assess, Acknowledge, Act (IDEA3) sexual assault resistance education intervention reduces sexual violence victimization in undergraduate women. Participants in the intervention group will be ask…
Sponsor: University of Maryland, College Park • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC